Company Evoke Pharma, Inc.

EVOK

US30049G2030

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Evoke Pharma, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-25 pm EDT			5-day change	1st Jan Change
0.436 ^USD	-2.57%		-8.94%	-58.49%

Apr. 24	Transcript : Evoke Pharma, Inc. - Special Call
Mar. 21	Evoke Pharma, Inc. Announces Board Changes as of March 31, 2024	CI

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.

Number of employees: 4

USD in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical Products 100.0 %	3	100.0 %	5	100.0 %	+106.51%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	3	100.0 %	5	100.0 %	+106.51%

Managers	Title	Age	Since
Matthew D'Onofrio CEO	Chief Executive Officer	54	06-12-31
Marilyn Carlson CTO	Chief Tech/Sci/R&D Officer	76	13-11-30

Members of the board	Title	Age	Since
Cam L. Garner FOU	Founder	75	06-12-31
Kenneth Widder BRD	Director/Board Member	71	07-05-31
Todd Brady BRD	Director/Board Member	52	07-05-31
Malcolm R. Hill BRD	Director/Board Member	67	07-05-31
Vickie Reed BRD	Director/Board Member	62	21-05-12

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	8,477,801	6,835,134 ( 80.62 %)	0	80.62 %

Name	Equities	%	Valuation
Bleichroeder Holdings LLC 9.731 %	825,000	9.731 %	503 250 $
AIGH Capital Management LLC 9.731 %	825,000	9.731 %	503 250 $
Altium Capital Management LP 9.708 %	822,986	9.708 %	502 021 $
Laurence Lytton 8.673 %	735,294	8.673 %	448 529 $
Vanguard Group, Inc. (Subfiler) 0.3521 %	29,851	0.3521 %	18 209 $
Cam L. Garner 0.3299 %	27,966	0.3299 %	17 059 $
Geode Capital Management LLC 0.3192 %	27,065	0.3192 %	16 510 $
David Gonyer 0.2762 %	23,416	0.2762 %	14 284 $
Matthew D'Onofrio 0.2339 %	19,833	0.2339 %	12 098 $
Tower Research Capital LLC 0.0760 %	6,446	0.0760 %	3 932 $

Evoke Pharma, Inc.

420 Stevens Avenue Suite 370

92075-2074, Solana Beach

+858 345 1494

http://www.evokepharma.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.436 USD

Average target price

7 USD

Spread / Average Target

+1,505.50%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
EVOKE PHARMA, INC.	-58.49%	3.79M
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.33%	358B
MERCK & CO., INC.	+19.90%	322B
ABBVIE INC.	+7.95%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-12.26%	149B
AMGEN INC.	-6.47%	146B

Other Pharmaceuticals